FMP
Acumen Pharmaceuticals, Inc.
ABOS
NASDAQ
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
3.18 USD
0.02 (0.629%)
About
ceo
Mr. Matt Zuga
sector
Healthcare
industry
Biotechnology
website
https://acumenpharm.com
exchange
NASDAQ
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
CIK
0001576885
ISIN
US00509G2093
CUSIP
00509G209
Address
427 Park Street
Phone
434 297 1000
Country
US
Employee
51
IPO Date
Jul 1, 2021
Summary
CIK
0001576885
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
00509G209
ISIN
US00509G2093
Country
US
Price
3.18
Beta
0.08
Volume Avg.
343.86k
Market Cap
191.05M
Shares
-
52-Week
1.81-11.31
DCF
0.74
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.94
P/B
-
Website
https://acumenpharm.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ABOS News
It looks like there's no news available.
